As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
News|Videos|February 26, 2026
Hospital Pharmacy and Supply Chain Leaders Want to Be Heard: Ready to Listen?
Author(s)Tecsys
Valerie Bandy and Ryan Rotar, both from Tecsys, examine how hospital pharmacy leaders are reshaping their expectations and prioritizing value-driven partnerships over traditional transactional vendor relationships. They explore the growing shift toward self-distribution and direct purchasing, as well as how transparency and proactive communication are now essential to mitigating logistics risk and safeguarding patient care. This interview stresses technology’s role as a critical enabler of data visibility, empowering manufacturers to build long-term trust through consistent performance and shared accountability.
Advertisement
Watch the video to learn more about:
- How hospital pharmacies evaluate manufacturers and what separates true partners from transactional vendors.
- Where direct purchasing changes expectations around risk, communication, logistics, and technology.
- Practical ways manufacturers can build trust, improve collaboration, and create long-term financial value with health systems.
Advertisement
Related to this article
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift to NDC-12.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's five-year evolution and where serialized data is creating value beyond compliance.
HDA's Kala Shankle unpacks the biggest open question on preemption and offers a two-step playbook for wholesalers and 3PLs preparing for national licensure.
Cardinal Health's Liberty Dewey outlines the four parallel work streams driving the NDC-12 transition, and why the biggest risk sits in trading partner handoffs rather than any single system.
Sponsored
Joe Reynolds, Head of User Experience Services at Noble, breaks down what it really takes for pharmaceutical companies to move therapy from the clinic into the patient's home.
Advertisement
Advertisement